[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-metastases-from-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-metastases-from-colorectal-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,80,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100587486","blood-clearance-kinetics-of-the-nucleosome-and-ctcf-in-peritoneal-metastasis-colorectal-cancer-100587486",false,"NCT06929013","Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.","Monitoring of Blood Clearance Kinetics of the Nucleosome and CTCF in Peri-operative Management of Peritoneal Metastasis Colorectal Cancer.","NUCLEAR","Inclusion Criteria:\n\n* Common criteria:\n\n  * Male\u002Ffemale over 18 years of age.\n  * Weight ≥ 55 kg at inclusion.\n  * Signature of a free and informed consent form.\n* Specific criteria:\n\nGroup 1:\n\n* Peritoneal metastases colorectal cancer histologically proven\n* Synchronous or metachronous peritoneal metastases.\n* Patients eligible for initial cytoreduction surgery.\n* Non mucinous tumor (mucinous cells contingent \\\u003C30%).\n\nGroup 2:\n\nColorectal cancer\n\nGroup 3:\n\nNon-oncological chronic inflammatory diseases\n\nGroup 4:\n\nNon-oncological chronic inflammatory diseases : parietal repairs, elective sigmoidectomy for diverticulosis\n\nGroup 5:\n\nAbdominal sepsis conditions: peritonitis due to digestive perforation in non-oncological pathology, non-perforated appendicitis, cholecystitis.\n\nNon inclusion Criteria:\n\n* Patient with an active cancer (excluding colorectal cancer).\n* Person with a progressive autoimmune disease.","ALL","18 Years",{"count":20,"type":21},58,"ESTIMATED","INTERVENTIONAL",[24],"NA","Colorectal cancer is highly prevalent in France, ranking second among women and third among men. Its primary metastatic sites include the liver, lungs, and peritoneum. For peritoneal metastases, when the disease is moderately extensive, cytoreductive surgery is recommended in an expert centre. Following this procedure, the surgeon uses the CC-Score (Completeness of Cytoreduction after Surgery Score) to assess the completeness of surgical resection by evaluating the largest remaining tumor residue. This subjective score is currently the main prognostic factor for oncological outcomes post-surgery. However, there is no objective score based on biological criteria to evaluate the radicality of resection, despite the hypothesis that the micrometastatic component of the disease could be biologically assessed using appropriate circulating markers.\n\nNew biomarkers are emerging and appear relevant for determining the presence of tumor residual disease. Notable among these are circulating tumor DNA, which can detect mutated DNA released by tumor cells into the patient's blood through high-throughput sequencing, and new markers related to epigenetic modifications in cancer cells. These markers target specific nucleosomes or the transcription factor CTCF and show promise in detecting residual disease.\n\nTo effectively use these markers for constructing a biological score to detect residual disease in peritoneal carcinomatosis, it is essential to understand their perioperative kinetics. This is crucial because cellular debris release is expected post-surgery, necessitating the determination of the most relevant time point for measurement. Additionally, these markers appear to be correlated with blood inflammation levels, requiring a description of this correlation to account for this potential confounding factor. Finally, the sensitivity and specificity of these markers must be determined by studying their perioperative kinetics in patient groups undergoing surgeries other than cytoreductions for peritoneal carcinomatosis.",[27,28],"Peritoneal Carcinomatosis","Peritoneal Metastases From Colorectal Cancer",[30,31,32,33],"Biomarkers","Peritoneal carcinomatosis","CTCF","Nucleosome","RECRUITING","2026-02-12",{"date":37,"type":38},"2026-02-13","ACTUAL",{"date":40,"type":38},"2025-05-06",{"date":42,"type":21},"2026-06-20",{"name":44,"class":45},"Hospices Civils de Lyon","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100617191","chewing-gum-flavors-to-reduce-postoperative-nausea-and-vomiting-after-pipac-100617191","NCT07315412","Chewing Gum Flavors to Reduce Postoperative Nausea and Vomiting After PIPAC","Comparative Effectiveness of Ginger-Mint and Cinnamon-Flavored Gum in Preventing Nausea and Vomiting Following Pressurized Intraperitoneal Aerosol Chemotherapy","Inclusion Criteria:\n\n* Adults aged 18 years or older undergoing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).\n* Able to communicate, understand study instructions, and provide written informed consent.\n* No known allergy or intolerance to ginger, mint, or cinnamon.\n* Able and willing to chew gum for 15 minutes.\n* Apfel risk score ≥3 for postoperative nausea and vomiting.\n\nExclusion Criteria:\n\n* Postoperative complications requiring intensive care or reoperation.\n* Need for rescue antiemetic medication within the first 2 postoperative hours.\n* History of psychiatric disorder, neurological disease, or cognitive impairment affecting participation.\n* Anatomical or functional limitation preventing chewing (e.g., full dentures, jaw restriction, oral surgery).\n* Known phenylketonuria or metabolic intolerance to chewing gum ingredients.\n* Active chemotherapy, radiotherapy, or immunosuppressive therapy affecting gastrointestinal function.","80 Years",{"count":56,"type":21},75,[24],"This randomized controlled clinical trial aims to evaluate the effectiveness of chewing gum with different natural flavors in reducing postoperative nausea and vomiting (PONV) following Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Adult patients undergoing PIPAC will be randomly assigned to one of three groups: (1) ginger-mint flavored gum, (2) cinnamon flavored gum, or (3) control group with standard postoperative care only. Participants in the intervention arms will chew one piece of gum for 15 minutes in the post-anesthesia care unit (PACU). Nausea intensity (Numeric Rating Scale, 0-10) and the presence of vomiting or retching will be assessed at baseline and every 15 minutes for 2 hours.\n\nThe study hypothesizes that ginger-mint and cinnamon flavored chewing gums, both plant-based and certified vegan, will be effective, non-pharmacological, and safe methods to reduce nausea and vomiting after PIPAC. This research may contribute to enhanced postoperative comfort and faster recovery by supporting the principles of Enhanced Recovery After Surgery (ERAS).",[60,28,61],"Postoperative Nausea and Vomiting (PONV)","Intraperitoneal Chemotherapy",[63,64,65,66,67,68,69],"Chewing gum","ginger","cinnamon","postoperative neusea","vomiting","eras","supportive care","NOT_YET_RECRUITING","2025-12-23",{"date":73,"type":38},"2026-01-02",{"date":75,"type":21},"2025-12-10",{"date":77,"type":21},"2027-05-30",{"name":79,"class":45},"Fenerbahce University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100611962","phase-1-cea-car-t-therapy-after-cytoreduction-in-colorectal-cancer-patients-with-peritoneal-metastases-100611962","NCT07247396","CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases","A Clinical Trial to Evaluate the Safety and Efficacy of CEA-Directed CAR-T Cell Immunotherapy in Patients With Advanced Colorectal Cancer and Peritoneal Metastases Following Cytoreductive Surgery","Inclusion Criteria:\n\n1. Aged ≥18 years and ≤75 years at the time of informed consent signing.\n2. Pathologically confirmed colorectal cancer with peritoneal metastases.\n3. Patients who have failed standard treatments (disease progression or intolerance, e.g., failure of oxaliplatin, irinotecan, fluorouracil, etc.) or have no effective treatment options.\n4. Underwent cytoreductive surgery for peritoneal metastases from colorectal cancer, with cytoreduction completeness (CC) score of CC-0 to CC-2. Postoperative recovery is good, without severe postoperative complications. A baseline enhanced whole-abdominal CT scan (within 1 week before or after 1 month post-surgery) shows no distant metastases outside the peritoneum (e.g., liver, lung, bone, brain).\n5. Tumor samples resected during cytoreductive surgery are confirmed CEA-positive by immunohistochemistry (distinct membranous staining, positive rate ≥10%).\n6. Regardless of synchronous or metachronous peritoneal metastases, there are no metastatic sites outside the peritoneum, and the primary tumor has been resected.\n7. Expected survival time of at least 3 months.\n8. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.\n9. Unless otherwise specified, subjects must have adequate organ function as follows:\n\n   1. Hematology: White blood cell (WBC) count ≥3.5×10⁹\u002FL, neutrophil count ≥1.8×10⁹\u002FL, lymphocyte count \\>0.5×10⁹\u002FL, platelet count ≥80×10⁹\u002FL, hemoglobin ≥90g\u002FL.\n   2. Cardiac function: Echocardiography shows left ventricular ejection fraction (LVEF) \\>50%, and electrocardiogram (ECG) shows no significant abnormalities.\n   3. Renal function: Serum creatinine ≤2.0×ULN, blood urea nitrogen (BUN) ≤1.5×ULN.\n   4. Liver function: ALT and AST ≤3.0×ULN; total bilirubin ≤2.0×ULN (≤3.0×ULN for Gilbert's syndrome).\n   5. Oxygen saturation \\>92% without oxygen supplementation.\n10. Women of childbearing potential have a negative pregnancy test within 7 days prior to enrollment, have no immediate plans for pregnancy, and agree to use contraceptive measures (or other fertility control methods) before and during the trial.\n11. Male patients agree to use appropriate contraceptive methods.\n12. Able to comply with the study protocol and follow-up procedures.\n\nExclusion Criteria:\n\n1. Unwilling to sign the informed consent form.\n2. Received or are currently receiving anti-tumor drug therapy within 2 weeks prior to enrollment, except for perioperative hyperthermic intraperitoneal chemotherapy.\n3. Clinically confirmed active or uncontrolled bacterial, fungal, or viral infections.\n4. Have other uncured malignant tumors, except for carcinoma in situ of the lung, carcinoma in situ of the cervix, or basal cell carcinoma of the skin.\n5. Have a history of severe asthma, active autoimmune disease, immunodeficiency, or require long-term immunosuppressive drug therapy; exceptions include vitiligo, type 1 diabetes, autoimmune-related hypothyroidism requiring hormonal therapy, and psoriasis not requiring systemic treatment.\n6. Have a history of mental illness.\n7. Have uncontrolled comorbidities, including but not limited to symptomatic congestive heart failure, unstable angina, arrhythmia; severe coronary artery disease or cerebrovascular disease, or other diseases deemed ineligible by the investigator.\n8. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with HBV DNA titer above the normal range; positive for hepatitis C virus (HCV) antibody with HCV RNA above the normal range; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis.\n9. Known hypersensitivity to any component of the study product, or other potential hypersensitivity to immunotherapy as deemed by the investigator.\n10. Pregnant or lactating women.\n11. The investigator judges that the patient has other serious diseases that may affect follow-up and short-term survival.\n12. Other situations deemed ineligible by the investigator.","75 Years",{"count":89,"type":21},12,[91],"PHASE1","This single-arm, open-label, dose-escalation trial aims to evaluate the safety and efficacy of CEA-targeted CAR-T cells and to obtain their pharmacokinetic profile in patients with advanced colorectal cancer and peritoneal metastases after cytoreductive surgery; the recommended dose will then be derived from these data.",[28],"2025-11-23",{"date":96,"type":38},"2025-11-25",{"date":98,"type":38},"2025-11-03",{"date":100,"type":21},"2027-10-31",{"name":102,"class":45},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100568424","phase-2-systemic-antitumor-treatment-with-or-without-pressurized-intraperitoneal-aerosol-chemotherapy-for-colon-peritoneal-metastases-pipox02-100568424","NCT06681038","Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)","Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Colon Peritoneal Metastases - a Multicentre Phase II Randomized Trial (PIPOX02)","PIPOX02","Inclusion Criteria:\n\n* ECOG performance status of 0 to 2;\n* Histopathologically confirmed colonic adenocarcinoma with synchronous or metachronous peritoneal metastasis (PM);\n* Unresectable PM defined as any of the following:\n\n  * PCI \\>15\n  * Extended small bowell involvement\n  * Poor general condition contra-indication to a major abdominal surgery (eg: a complete cytoreductive surgery), as decided by the medico-surgical team of the investigator's site specialised in peritoneal carcinomatosis in charge of the patient.\n* A surgical exploration performed less than 4 weeks before inclusion (if not, a laparoscopic exploration must be performed);\n* First line systemic chemotherapy for advanced \u002F metastatic colonic adenocarcinoma. Systemic chemotherapy in an adjuvant setting is allowed if completed more than 6 months before recurrence and without persistent oxaliplatin-induced neuropathy;\n* No extended intraperitoneal adherences defined by at least 9 out of 13 abdominal regions correctly explored during surgical exploration (laparoscopy or laparotomy;\n\nExclusion Criteria:\n\n* Other cancer treated within the last 3 years, with the exception of in situ cervical carcinoma or basocellular carcinoma;\n* Rectal cancer primary (tumor \\\u003C15 cm from the anal verge);\n* Mutational status corresponding to microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR);\n* Complete or partial bowel obstruction unresponsive to medical treatment;\n* Extraperitoneal polymetastatic diseases. (Only oligometastatic1 diseases are allowed for inclusion);\n* History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess within 6 months prior to enrolment;\n* Active gastrointestinal bleeding;\n* Inflammatory bowel disease;\n* Peripheral neuropathy according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0, grade ≥2",{"count":112,"type":21},114,[114],"PHASE2","The goal of this clinical trial is to learn if Pressurized intraperitoneal aerosol chemotherapy (PIPAC) significantly improve the progression-free survival (PFS) in patients with advanced peritoneal metastasis from colorectal cancer.\n\nResearchers will compare 2 strategies, systemic treatments (chemotherapy + targeted therapy) corresponding to standard treatment with or without intraperitoneal oxaliplatin (PIPAC) to see if PIPAC improve the progression-free survival.\n\nParticipants will:\n\n* receive a standard treatment every 2 weeks for 12 cycles of intravenous FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF) in the both arms.\n* receive up to a maximum of 4 PIPAC every 6 weeks with pressurized aerosol containing oxaliplatin in experimental arm.\n* receive a maintenance treatment until progression or until the onset of severe toxicity after 12 cycles.\n* be asked to perform a CT scan and carcinoembryonic antigen (CEA) assay every 8 weeks until progression",[117],"Peritoneal Metastases from Colorectal Cancer",[119,120,121,122],"Surgical oncology","Peritoneal metastasis","Pressurized IntraPeritoneal Aerosol Chemotherapy","Systemic chemotherapy","2024-11-07",{"date":125,"type":38},"2024-11-08",{"date":127,"type":21},"2025-02",{"date":129,"type":21},"2029-08",{"name":131,"class":45},"Institut Cancerologie de l'Ouest",15]